Posit Science's BrainHQ trial links brain training to acetylcholine marker
The completed INHANCE trial reported a PET imaging signal after speed-of-processing training, with no effect size or p-value disclosed on the record and no controlled comparator drug to benchmark it against.
Executive Summary
- A randomized trial testing whether computerized speed-of-processing brain training changes a brain-imaging marker tied to the cholinergic system finished enrollment and posted its primary outcome data.
- The sponsor's public disclosure bundles this result with a separate, newer study and an older, larger trial to argue for a cumulative body of evidence on cognitive training and Alzheimer's-related biology, a framing that invites scrutiny of what each individual study actually showed.
- The posted outcome data describe a between-group imaging comparison without a disclosed effect size, statistical test result, or confidence interval, leaving the strength of the finding unclear against the trial's own comparator arm.
- No trial in the broader cognitive-decline landscape shares this training program's modality, so the result stands without a direct precedent to benchmark against, and its significance rests entirely on its own data rather than a comparative track record.
The readout
NCT04149457, known as INHANCE, enrolled 93 adults aged 65 and older and randomized them to either computerized speed-of-processing training or an active comparator arm using non-speeded computerized training. The registered primary outcome was change in FEOBV standardized uptake value ratio, a PET imaging measure of the brain's acetylcholine system, in the anterior cingulate cortex, measured at three months post-intervention. The trial completed in June 2024 and posted results to the public registry on July 13, 2026, more than two years after primary completion. A press release the same week described the finding as neuroimaging evidence of upregulated acetylcholine production, framed as equivalent to roughly a 10-year age reversal on that marker. NCT04149457+1Improving Neurological Health in Aging Via Neuroplasticity-based Computerized ExerciseNCT04149457Brain Training Shown to Reduce Amyloid Indicative of Alzheimer’sJul 13, 2026
What the trial can and cannot establish
INHANCE randomized participants against an active comparator, not a passive or waitlist control, which is the more rigorous design for isolating a training-specific effect from generic engagement effects. The posted outcome module reports the measurement approach, mean change, and 95% confidence interval for the primary PET outcome, but the underlying between-group numbers are not resolved in the current record, and no p-value is attached to the comparison. Adverse events were low-grade: no deaths and no serious events in either arm, with mild dry mouth and mild oral sensation reported as the most frequent non-serious findings. NCT04149457Improving Neurological Health in Aging Via Neuroplasticity-based Computerized ExerciseNCT04149457
The sponsor's framing
The July 2026 disclosure does not stand alone. It ties INHANCE to a newer 53-person biomarker study called ENACT, which reported an improvement in blood amyloid ratios after 20 hours of the same training, and to the NIH-funded ACTIVE trial's 20-year follow-up, which reported a 25% reduction in Alzheimer's diagnoses in Medicare records after 23 hours of training in the first three years. Posit Science, which makes BrainHQ, quotes its own CEO describing the three studies together as telling "a very coherent and important story" about training-driven brain remodeling. That is a company characterizing its own commercial product across three separate trials with different designs, endpoints, and populations, which is why each study's individual result bears separate scrutiny. BrainBrain Training Shown to Reduce Amyloid Indicative of Alzheimer’sJul 13, 2026
The competitive field
Cognitive Decline trials in the broader landscape span mechanisms with no relationship to computerized training, including a thrombin inhibitor for atrial fibrillation, an amyloid PET tracer, and a serotonin reuptake inhibitor, none of which share BrainHQ's modality or target. No competitor trial in the supplied set uses the same intervention type, so INHANCE has no direct comparator to benchmark its PET-imaging result against, and its significance rests on replication within the sponsor's own study series rather than an external precedent.
Operational history
The trial's primary completion date moved four times between 2021 and 2023, from September 2021 out to May 2024, and its enrollment target was revised from 108 down to 92 before finishing at 93, a pattern the registry-churn tool labels moderate instability. The trial nonetheless completed on its final guided date in June 2024, and results posted in mid-2026, more than two years later. NCT04149457Improving Neurological Health in Aging Via Neuroplasticity-based Computerized ExerciseNCT04149457
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.